The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer
Abstract
The sodium/iodide symporter (NIS) mediates iodide uptake in the thyroid gland and lactating breast. NIS mRNA and protein expression are detected in most thyroid cancer specimens, although functional iodide uptake is usually reduced resulting in the characteristic finding of a ‘cold’ or non-functioning lesion on a radioiodine image. Iodide uptake after thyroid stimulating hormone (TSH) stimulation, however, is sufficient in most differentiated thyroid cancer to utilize β-emitting radioactive iodide for the treatment of residual and metastatic disease. Elevated serum TSH, achieved by thyroid hormone withdrawal in athyreotic patients or after recombinant human thyrotropin administration, directly stimulates NIS gene expression and/or NIS trafficking to the plasma membrane, increasing radioiodide uptake. Approximately 10–20% differentiated thyroid cancers, however, do not express the NIS gene despite TSH stimulation. These tumors are generally associated with a poor prognosis. Reduced NIS gene expression in thyroid cancer is likely due in part, to impaired trans-activation at the proximal promoter and/or the upstream enhancer. Basal NIS gene expression is detected in about 80% breast cancer specimens, but the fraction with functional iodide transport is relatively low. Lactogenic hormones and various nuclear hormone receptor ligands increase iodide uptake in breast cancer cells in vitro, but TSH has no effect. A wide range of ‘differentiation’ agents have been utilized to stimulate NIS expression in thyroid and breast cancer using in vitro and in vivo models, and a few have been used in clinical studies. Retinoic acid has been used to stimulate NIS expression in both thyroid and breast cancer. There are similarities and differences in NIS gene regulation and expression in thyroid and breast cancer. The various agents used to enhance NIS expression in thyroid and breast cancer will be reviewed with a focus on the mechanism of action. Agents that promote tumor differentiation, or directly stimulate NIS gene expression, may result in iodine concentration in ‘scan-negative’ thyroid cancer and some breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy
DOW, K. H., FERRELL, B. R., & ANELLO, C. (1997) · Thyroid · doi:10.1089/thy.1997.7.613 · Cited by 289 · cited 2×
“This is achieved either by withdrawal of thyroid hormone replacement after a total thyroidectomy or by administration of rhTSH (Dow et al. 1997).”
BackgroundHuman Chorionic Gonadotropin and the Thyroid: Hyperemesis Gravidarum and Trophoblastic Tumors
HERSHMAN, J. M. (1999) · Thyroid · doi:10.1089/thy.1999.9.653 · Cited by 154
Cited by
Bonnema, S. J., & Hegedüs, L. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1030 · Cited by 339
Oh, J. M., & Ahn, B.-C. (2021) · Theranostics · doi:10.7150/thno.57689 · Cited by 163
Lang, B. H.-H., Wong, I. O. L., Wong, K. P., Cowling, B. J., & Wan, K.-Y. (2012) · Surgery · doi:10.1016/j.surg.2011.12.019 · Cited by 82
Metadata
- Authors
- Kogai, T., Taki, K., & Brent, G. A.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2006-09
- Volume
- 13
- Issue
- 3
- Pages
- 797-826
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2140907576
- Cited by
- 203
- References
- 3
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.